Cowen raised its price target on Hologic (NASDAQ: HOLX) to $45.00 (from $44.00) while maintaining an Outperform rating.

Analyst Doug Schenkel commented, "Hologic beat FQ3 revenue and EPS expectations even adjusted for favorable non-core items. While there are numerous moving parts, updated full year guidance was largely in line with our expectations. Subsequent to a prolonged period of very disappointing execution, FQ3 performance was a step in the right direction. Challenges persist but are arguably priced in at the current valuation."